TAIPEI, June 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that Foresee's oral ALDH2 activator, mirivadelgat, has been selected to enter clinical testing in...
~ Godrej DEI Lab Launches Queer India Now!, a new anthology Under Queer Directions ~~ Introduces 'Queer India Fellowship' to Nurture Emerging Queer Leaders...
SHANGHAI, June 8, 2026 /PRNewswire/ -- On June 8, PATEO (02889.HK) disclosed a voluntary announcement, announcing that it has signed a tripartite strategic cooperation framework...
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- LG and NVIDIA are expanding their strategic collaboration across industries, Physical AI, AI Infra and mobility...
HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...
A Gap Year or Academic Year abroad is far more than a year off, it's an opportunity for young people to gain life experience and improve language skills.
Increased AI deployment results in an aggregated net hiring effect of +27% expected in 2026, while upskilling internal talent emerges as the primary strategy...
Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% of respondents say they're completely prepared for the scale of AI...
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Daekyo Culture Foundation and the World Youth Culture Foundation announce the opening of submissions for the 34th...
Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6
RIO DE JANEIRO, June 07, 2026 (GLOBE NEWSWIRE) -- Air Canada and Abra Group today announced they have signed a Memorandum of Understanding to develop a broad, long-term strategic partnership. The agreement between Canada’s largest airline and the Latin American air transport company, whose carriers include the Avianca and GOL brands, would enable the partners to expand their global reach, providing customers and shippers greater connectivity across North, Central and South America and beyond. Any final agreement is subject to final documentation and regulatory approval.